Immutep receives A$1,437,826 R&D Tax Incentive
Filed with ASX · · 2 pages · English
SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2019 fiscal year, mainly related to the Company’s TACTI-mel and TAC
Story so far
Earlier from Immutep
- Immutep announces improving data from TACTI-002 ph II trial
- Immutep receives $3.6M R&D French tax incentive
- Immutep granted Japanese patent for eftilagimod alpha
- INSIGHT-004 and TACTI-002 data to be presented at ASCO
- Immutep Investor Presentation
Later from Immutep
- Immutep Completes Recruitment for Part A of TACTI-002 trial
- US patent granted for IMP701 antibody
- Immutep granted US patent for eftilagimod alpha
- Recruitment of stage 1 of part B in TACTI-002 study complete
- Appendix 4E & 2020 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep